You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials Completed
359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to March 2024

AbstractFullPdf
Nov 2021361016
Dec 2021104010
Jan 20227403
Feb 202288014
Mar 2022274011
Apr 20227007
May 202284012
Jun 202242012
Jul 20225804
Aug 202210207
Sep 202266014
Oct 2022114016
Nov 20225409
Dec 20223403
Jan 20233401
Feb 20234601
Mar 20236007
Apr 20236609
May 20236209
Jun 20234205
Jul 202344013
Aug 20232406
Sep 20232603
Oct 20233402
Nov 20234207
Dec 20234405
Jan 20241203
Feb 20243403
Mar 20243400
Total21290212